Search results
Showing 3496 to 3510 of 8905 results
Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices.
Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)
Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).
Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy.
PredictSURE IBD and IBDX to guide treatment of Crohn's disease (HTG610)
Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease.
SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (HTG598)
Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea.
Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.
Testing strategies for Lynch syndrome in people with endometrial cancer (HTG557)
Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer.
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (HTG553)
Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke.
Read the biographies of our medical technologies advisory committee members.
Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.
Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)
Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.